Application Comparison of the Neutral Red Assay and the MTT/CCK-8 Assays in Cytotoxicity Testing
Application Comparison of the Neutral Red Assay and the MTT/CCK-8 Assays in Cytotoxicity Testing
Differences in cytotoxicity evaluation arise first from differences in the biological process being measured. The Neutral Red assay primarily reflects cellular uptake of the dye and lysosomal retention capacity, whereas the MTT assay and the CCK-8 assay mainly reflect dehydrogenase-related intracellular reductive metabolic activity. All three methods can be used for cell viability analysis, but their biological meaning, technical limitations, and suitable application scenarios are not the same.
Keywords: cytotoxicity; Neutral Red assay; MTT; CCK-8; lysosomal function; dehydrogenase activity; metabolic activity; method comparison
1. Technical background of cytotoxicity testing
1.1 Major components of cytotoxicity readouts
(1) Changes in cell number
The most intuitive manifestation of cytotoxicity is a decrease in cell number, including inhibition of proliferation, increased cell detachment, and accumulation of cell death. It should be noted that most plate-based colorimetric methods do not directly count cells, but instead indirectly reflect toxic effects through changes in cell functional status.
(2) Changes in metabolic activity
Metabolic suppression often appears earlier than overt morphologic collapse and decline in total cell number. For methods based on tetrazolium salt reduction or dehydrogenase activity, signal reduction primarily corresponds to altered metabolic status rather than necessarily indicating cell death.
(3) Changes in organelle function
Some treatments primarily affect lysosomes, mitochondria, endocytic systems, or membrane transport processes. Such damage may not initially manifest as marked cell death, but can generate clear signal changes in specific assays.
(4) Loss of cellular homeostasis
Changes in membrane integrity, ion gradients, acidic organelle status, and transmembrane transport capacity can all affect endpoint readouts in different assay systems. Therefore, reduced cell viability is fundamentally a composite manifestation of multilevel biologic changes.
1.2 Core dimensions for method comparison
(1) Detection target
This refers to the specific cellular process directly read out by the method. It determines whether the result more closely reflects organelle function, metabolic activity, or overall growth state.
(2) Signal generation pathway
Different staining or color development mechanisms confer different sensitivities to sample background, culture conditions, and cell status.
(3) Workflow
Whether the method requires washing, medium replacement, crystal solubilization, or dye extraction directly affects intra-assay reproducibility and the level of operator-dependent error.
(4) Sources of interference
Sample color, turbidity, adsorption properties, reducing activity, and precipitation behavior may all produce assay-specific interference.
(5) Downstream suitability
This includes suitability for high-throughput screening, multi-time-point observation, evaluation of weakly adherent cells, and cytotoxicity analysis of complex samples.
Table 1. Main dimensions for comparing cytotoxicity methods
Comparison Dimension | Key Focus | Impact on Result Interpretation |
Detection target | Cellular process measured directly | Determines the biologic level represented by the result |
Signal generation pathway | Dye uptake, enzymatic reduction, or soluble chromogenic reaction | Determines sensitivity to specific sources of interference |
Workflow | Whether washing, crystal solubilization, or dye extraction is required | Determines reproducibility and intra-assay stability |
Sources of interference | Background color, reducing activity, adsorption, turbidity | Determines whether methodological artifacts may occur |
Application suitability | Throughput, time-point design, cell-type compatibility | Determines practical usability in specific experimental settings |
2. Neutral Red assay
2.1 Detection principle of the Neutral Red assay
(1) Dye uptake mechanism
Neutral Red is a weak cationic dye. Viable cells can internalize it through membrane transport and endocytic processes, after which it accumulates in acidic lysosomes.
(2) Intracellular retention mechanism
When cells maintain normal membrane integrity, energy status, and lysosomal acidification capacity, they can retain Neutral Red stably. If membrane transport capacity declines, lysosomal acidification is impaired, or lysosomal membrane stability decreases, intracellular accumulation is reduced.
(3) Nature of the readout
The Neutral Red assay does not measure cell number itself, but rather the ability of cells to uptake, accumulate, and retain the dye. Accordingly, this method is more closely related to organelle function and overall cellular homeostasis.
2.2 Experimental workflow of the Neutral Red assay
(1) Cell seeding and treatment
Seeding density should be set according to cell type so that the control group is in a suitable comparison state at the experimental endpoint. After cells stabilize, test samples are added and the preset exposure period is completed.
(2) Neutral Red staining
At the end of treatment, Neutral Red working solution is added and incubation continues. Stable dye concentration, incubation time, and temperature should be maintained at this stage to reduce well-to-well variation.
(3) Washing and removal of free dye
After staining, free dye is removed and gentle washing is performed. Insufficient washing increases background, whereas excessive washing may cause cell loss.
(4) Extraction and readout
An extraction solution is added to release intracellularly retained Neutral Red, and relative viability is then calculated from absorbance measurements.
2.3 Cellular status reflected by the Neutral Red assay
(1) Lysosomal functional status
A decrease in Neutral Red signal usually suggests reduced lysosomal acidification capacity, impaired vesicular transport, or weakened intracellular retention.
(2) Membrane transport and endocytic capacity
When a test factor primarily affects membrane transport and endocytosis, the Neutral Red assay often reveals differences at an earlier stage.
(3) Integrity of cellular homeostasis
The Neutral Red assay is relatively sensitive to subtoxic states in which large-scale cell death has not yet occurred but organelle function has already been impaired.
2.4 Advantages of the Neutral Red assay
(1) Independent detection dimension
This method does not depend on dehydrogenase activity or tetrazolium salt reduction, and therefore provides information independent of metabolic assays.
(2) Sensitivity to membrane system and lysosomal injury
For surfactants, endocytosis-related carriers, cationic polymers, and certain nanomaterials, the Neutral Red assay often has relatively strong discriminatory power.
(3) Suitable for validation of complex samples
In studies of natural products, complex formulations, and material extracts, the Neutral Red assay can serve as a second-dimension validation method and improve result reliability.
2.5 Limitations and interferences of the Neutral Red assay
(1) Multiple operational steps
The Neutral Red assay includes staining, plate washing, and extraction steps, resulting in multiple handling points. Intra-assay consistency therefore depends more strongly on operator experience.
(2) Moderate suitability for weakly adherent cells
Weakly adherent cells or cells that undergo marked shrinkage after treatment are more easily lost during washing, thereby exaggerating the apparent toxic effect.
(3) Results should not be directly equated with cell death
Some treatments mainly affect lysosomal acidification and intracellular transport. Even without causing substantial death, they can still reduce Neutral Red signal. Therefore, such results should first be interpreted as organelle functional injury rather than directly as increased cell death.
(4) Susceptibility to background color and material adsorption
Colored samples, adsorptive particles, and certain polymeric materials may affect extraction-solution readouts. Cell-free background wells and material blank wells must therefore be included.
3. MTT assay
3.1 Detection principle of the MTT assay
(1) Tetrazolium reduction mechanism
MTT is a yellow tetrazolium salt. Multiple intracellular reductive enzyme systems in viable cells can reduce it to purple insoluble formazan crystals.
(2) Level of detection
Because this reaction depends on overall cellular reductive metabolic status, MTT results mainly reflect cellular reducing capacity and metabolic activity rather than direct viable cell counts.
(3) Methodological characteristics
The MTT assay is more suitable as an endpoint method for metabolic activity evaluation and is appropriate for comparing treatment differences at a specific time point.
3.2 Experimental workflow of the MTT assay
(1) Cell exposure
After cell seeding and sample treatment are completed, MTT working solution is added at the experimental endpoint.
(2) Formazan crystal formation
Cells are incubated further to allow viable cells to reduce MTT to formazan crystals. Reaction time must be optimized according to cell status and assay background.
(3) Crystal solubilization
After incubation, solvent is added to dissolve the formazan completely. This step is one of the major sources of error in the MTT assay.
(4) Absorbance measurement
Absorbance is measured and relative viability is calculated against the control group. If crystal distribution is uneven or dissolution is incomplete, well-to-well variation increases markedly.
3.3 Cellular status reflected by the MTT assay
(1) Reductive metabolic capacity
A decrease in MTT signal primarily indicates reduced overall cellular reducing capacity and metabolic activity.
(2) Endpoint viability state
Because MTT is typically used as an endpoint assay, its result is closer to the integrated metabolic outcome at a fixed time point.
(3) Metabolic decline and cell death are not necessarily synchronous
Some samples suppress metabolism first and induce cell death later. Therefore, a decrease in MTT signal should not be mechanically interpreted as reduced cell number.
3.4 Advantages of the MTT assay
(1) Classical method
The MTT assay has a long history of use and extensive literature support, which facilitates comparison with existing results.
(2) Clear endpoint differences
For samples that strongly suppress metabolism, the MTT assay often generates clear intergroup differences.
(3) Suitable for continuity in traditional projects
For laboratories that have built long-term datasets using MTT, this method helps maintain continuity within ongoing projects.
3.5 Limitations and interferences of the MTT assay
(1) Crystal handling increases error
The location of formazan formation, crystal size, and completeness of dissolution can all substantially influence result stability.
(2) Strong interference from reductive samples
Some antioxidants, metal ions, nanoparticles, or complex formulations may directly participate in the reaction and generate non-cell-derived signals.
(3) Unsuitable for repeated multi-time-point measurements
Because MTT requires endpoint crystal formation followed by solubilization, it is generally not suitable for continuous tracking in the same well.
(4) Limited suitability for complex systems
In systems with high turbidity, strong background, or marked precipitation, result stability is usually inferior to that of CCK-8.
4. CCK-8 assay
4.1 Detection principle of the CCK-8 assay
(1) WST-8 chromogenic mechanism
The CCK-8 assay is typically based on the conversion of WST-8 into a water-soluble formazan product under the action of cellular dehydrogenases.
(2) Fundamental relationship to MTT
CCK-8 and MTT are both metabolic activity assays, and in both cases the detection target is related to dehydrogenase-associated metabolic processes. However, CCK-8 does not require crystal solubilization and therefore has a simpler workflow.
(3) Nature of the readout
CCK-8 results mainly reflect dehydrogenase activity and metabolic status, and should not be directly equated with absolute changes in cell number.
4.2 Experimental workflow of the CCK-8 assay
(1) Cell treatment
After cell seeding and sample exposure are completed, CCK-8 working solution is added directly to each well.
(2) Incubation and color development
Incubation continues under culture conditions, allowing cells to convert the substrate into a soluble chromogenic product.
(3) Direct measurement
After incubation, absorbance can be measured directly without medium removal, washing, or crystal solubilization.
4.3 Cellular status reflected by the CCK-8 assay
(1) Dehydrogenase activity
CCK-8 results primarily reflect dehydrogenase-related metabolic status.
(2) Dynamic metabolic changes
Compared with MTT, CCK-8 is more suitable for observing trends in viability across different time points.
(3) Early stimulatory effects
Some samples can transiently increase metabolic activity at low doses or short exposure times, leading to elevated CCK-8 signals. Such increases do not necessarily indicate enhanced proliferation.
4.4 Advantages of the CCK-8 assay
(1) Simple workflow
No crystal solubilization or complex postprocessing is required, which significantly reduces operator-dependent error.
(2) Suitable for high throughput
It is highly suitable for plate-based screening involving many samples, multiple doses, and multiple replicates.
(3) Suitable for multi-time-point design
It is convenient for time-course analyses at 24 h, 48 h, 72 h, and similar time points.
(4) Better suitability for weakly adherent cells
Because it minimizes mechanical handling, it is more favorable for weakly adherent or suspension cells.
4.5 Limitations and interferences of the CCK-8 assay
(1) Still a metabolic assay
Any factor affecting dehydrogenase activity or electron transfer processes can alter the endpoint result.
(2) Sample background can still interfere
Colored extracts, medium background, serum components, and complex formulations may affect absorbance, so background-correction wells must be included.
(3) High-density conditions can enter a nonlinear range
When cell density is too high or color development time is too long, the signal may enter a saturation range and reduce discrimination between groups.
Table 2. Core comparison of the Neutral Red assay, MTT assay, and CCK-8 assay
Comparison Dimension | Neutral Red Assay | MTT Assay | CCK-8 Assay |
Core detection target | Lysosomal uptake and retention | Reductive metabolic capacity | Dehydrogenase activity |
Main biologic level reflected | Organelle function and homeostasis | Endpoint metabolic activity | Dynamic metabolic activity |
Operational complexity | Moderately high | Moderate | Low |
Whether plate washing is required | Yes | Usually not a core step | Usually not required |
Whether crystal solubilization/extraction is required | Dye extraction required | Crystal solubilization required | Not required |
High-throughput suitability | Moderate | Moderate | High |
Suitability for multi-time-point analysis | Moderate | Low | Good |
Suitability for weakly adherent cells | Moderate | Moderate | Relatively high |
5. Main reasons for inconsistent results among the three methods
5.1 Differences in detection level
(1) The Neutral Red assay preferentially reflects organelle function
When a sample mainly affects membrane transport, endocytosis, and lysosomal acidification, the Neutral Red assay usually changes earlier.
(2) MTT and CCK-8 preferentially reflect metabolic status
When a sample mainly suppresses dehydrogenase activity and overall metabolic processes, MTT and CCK-8 are usually more sensitive.
(3) Divergent results are informative
Inconsistent results among different methods usually suggest differences in the site of action, detection dimension, or source of interference, rather than simply indicating experimental failure.
5.2 Differences in sources of interference
(1) Neutral Red assay
More susceptible to washing, cell detachment, and material adsorption.
(2) MTT assay
More susceptible to reductive samples, crystal formation, and the crystal solubilization process.
(3) CCK-8 assay
More susceptible to metabolic background, color-development saturation, and the color of the culture system.
5.3 Cellular states are not intrinsically synchronous
(1) Metabolic decline may precede cell death
This is commonly seen in MTT and CCK-8 assays.
(2) Organelle injury may precede metabolic collapse
This is a situation more readily detected first by the Neutral Red assay.
(3) Proliferation inhibition is not equivalent to immediate cell death
All three methods may show different sensitivities to states in which proliferation slows but large-scale cell death has not yet occurred.
6. Selection strategies under different experimental goals
6.1 Drug and small-molecule screening
(1) Large-scale primary screening
CCK-8 is preferred to improve throughput and efficiency.
(2) Endpoint confirmation
If continuity with traditional assay systems is needed, MTT may be added for endpoint validation.
(3) Mechanistic supplementation
If metabolic inhibition must be distinguished from organelle functional injury, the Neutral Red assay may be added.
6.2 Natural products, extracts, and colored samples
(1) Stronger background control is required
Cell-free blank wells and sample background wells must be included.
(2) A single metabolic assay is not sufficient
It is more appropriate to combine one metabolic assay with the Neutral Red assay.
(3) Microscopic morphology has supplementary value
For samples with high background and high turbidity, morphologic observation improves the strength of result interpretation.
6.3 Nanomaterials and polymer systems
(1) The risk of error from a single method is higher
Nanomaterials may adsorb dyes, scatter light, or directly participate in electron transfer.
(2) Two methods based on different principles are recommended
For example, CCK-8 combined with the Neutral Red assay, or MTT combined with the Neutral Red assay.
(3) Mechanistic indicators should be added when necessary
Such as LDH release, ROS, mitochondrial membrane potential, or apoptosis analysis, to improve the robustness of conclusions.
Table 3. Recommended strategies under different experimental goals
Experimental Goal | More Recommended Method | More Recommended Supplementary Method | Main Reason |
Large-scale drug primary screening | CCK-8 | MTT | High throughput; suitable for rapid screening and endpoint validation |
Endpoint metabolic activity comparison | MTT | CCK-8 | Classical endpoint assay; convenient for comparison with existing datasets |
Lysosomal/membrane system injury studies | Neutral Red assay | CCK-8 | Allows simultaneous evaluation of organelle function and metabolic status |
Toxicity of nanomaterials or complex extracts | CCK-8 or MTT + Neutral Red assay | Morphology / LDH | Reduces the risk of interference from a single method |
Evaluation of weakly adherent or suspension cells | CCK-8 | Neutral Red assay | Reduces cell loss caused by washing and crystal solubilization |
7. Products related to cytotoxicity experiments
Table 4. Common basic reagents for cytotoxicity experiments
Name | CAS No. | Applicable Experimental Step | Key Use | Notes for Use |
Neutral Red | Core detection system for the Neutral Red assay | Used to evaluate cellular dye uptake and lysosomal retention capacity; suitable for observing membrane transport- and acidic organelle-related injury | Staining time, washing intensity, and extraction conditions strongly affect reproducibility; special care is required for weakly adherent cells | |
MTT | Core detection system for the MTT assay | Used to evaluate cellular reductive metabolic activity and endpoint viability status | Formazan crystal formation and dissolution should be carefully controlled to avoid absorbance fluctuation caused by uneven crystallization between wells | |
XTT | Extended tetrazolium-based viability detection system | Used as a supplementary system for comparison of tetrazolium-based cell proliferation and cytotoxicity readouts | More suitable for methodological extension and comparison; does not directly replace the high-throughput advantage of CCK-8 | |
Dimethyl sulfoxide (DMSO) | MTT crystal solubilization step | Used to dissolve the insoluble formazan crystals formed after the MTT reaction | Solubilization time and mixing consistency must be controlled to prevent residual crystals from affecting absorbance stability | |
Triton X-100 | Establishment of positive injury controls | Used to artificially disrupt membrane structure and construct a clear positive control for toxicity or lytic injury | Treatment concentration should be optimized in pilot experiments; excessive treatment may cause global cell detachment and affect plate-based comparisons | |
Sodium dodecyl sulfate (SDS) | Strong membrane injury/lysis control | Used to establish a reference group with high-intensity cell injury or lysis | More suitable as a strong positive injury control and not as a substitute for routine toxicity treatment conditions | |
Fluorescein diacetate (FDA) | Supplementary viability validation | Used to supplement evaluation of intracellular esterase activity and help distinguish samples with “intact membrane but suppressed metabolism” | Suitable for combined use with the Neutral Red assay or CCK-8 assay; should not replace routine toxicity endpoints when used alone | |
Propidium iodide (PI) | Supplementary membrane integrity validation | Used to evaluate the proportion of membrane-damaged cells and provide mechanistic supplementation to metabolic assay results | Better suited for use with Annexin V or fluorescence imaging; does not directly replace the Neutral Red, MTT, or CCK-8 assays | |
Calcein AM | Supplementary live-cell fluorescence validation | Used to supplement observation of intracellular esterase activity and membrane integrity-related status in viable cells | Suitable for fluorescence validation in complex samples or material-surface experiments, complementing plate-based absorbance assays | |
JC-1 | Supplementary mitochondrial function validation | Used to evaluate mitochondrial membrane potential changes and help determine whether metabolic decline is associated with mitochondrial injury | Better suited as a mechanistic supplementary indicator and not as a replacement for the primary detection methods |
Table 5. Products related to primary cytotoxicity assay methods
Catalog No. | Name | Grade and Purity | Suitable Research Use/Application |
Neutral Red Stain Solution (1/3000) | BioReagent, biological stain, for microscopy | Suitable for the basic staining workflow of the Neutral Red assay; can be used to evaluate cellular uptake of Neutral Red and lysosomal retention capacity, and is applicable to routine cell viability and cytotoxicity analysis. | |
Neutral Red Ethanolic Staining Solution (0.1%) | BioReagent, biological stain, for microscopy, 0.1% | Suitable for preparation of Neutral Red assay staining systems and method comparison; can be used to assess Neutral Red uptake under specific treatment conditions and to optimize assay conditions across different concentration systems. | |
Neutral Red Stain Solution (0.5%) | BioReagent, biological stain, for microscopy, 0.5% in deionized water | Suitable for preparation of working solutions in the Neutral Red assay and optimization of staining conditions; can be used to analyze lysosomal uptake and retention signals in different cell models. | |
Neutral Red Staining Solution (1%) | BioReagent, biological stain, for microscopy, 1% | Suitable for high-concentration stock solution preparation or method development in the Neutral Red assay; can be used to establish cell viability evaluation systems under different staining concentration conditions. | |
Neutral Red Staining Solution for Live Cells | BioReagent, biological stain, for microscopy, sterile | Suitable for live-cell Neutral Red staining and cell viability observation; can be used in studies of live-cell uptake capacity, lysosomal function, and cytotoxicity. | |
Neutral Red Staining Solution (Vacuolar System Specific) | BioReagent, biological stain, for microscopy | Suitable for staining and functional studies of vacuolar/lysosomal structures; can be used for cytotoxicity and organelle injury evaluation with emphasis on changes in acidic vesicular systems. | |
MTT Cell Proliferation and Cytotoxicity Assay Kit | BioReagent | Suitable for endpoint evaluation of cell viability and cytotoxicity by the MTT assay; can be used for methodological comparison with the Neutral Red and CCK-8 assays | |
MTT Solution [for Cell proliferation assay] | 5.0 mg / mL in PBS | Suitable for building customized MTT assay systems for endpoint metabolic activity evaluation and condition optimization | |
XTT Cell Proliferation and Cytotoxicity Assay Kit | BioReagent | Suitable for extended comparison of tetrazolium-based cell viability assays and as a supplementary reference for MTT/CCK-8-related systems | |
Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (DNPH, Micro Method) | BioReagent | Suitable for endpoint cytotoxicity validation, especially for distinguishing “metabolic suppression” from “membrane disruption” when used with metabolic assays | |
LDH Cytotoxicity Assay Kit with WST-8 | BioReagent, ready-to-use, for IP | Suitable for rapid establishment of LDH-release cytotoxicity workflows as a supplementary plate-based toxicity assay | |
Live & deadtm animal cell viability / toxicity detection kit (calcein am, ethd-1) | — | Suitable for fluorescence-based stratification of viable and damaged cells, serving as a live/dead validation system beyond the Neutral Red, MTT, and CCK-8 assays | |
Viability/Cytotoxicity Assay Kit for Live & Dead Cells (Calcein AM/PI) | BioReagent, for microscopy, biological stain, suitable for immunofluorescence (IF), suitable for fluorescence analysis, for cell culture | Suitable for microscopic live/dead stratification analysis and can supplement plate-based absorbance assay results | |
Luminescent 3D Cell Viability Assay Kit | BioReagent | Suitable for cell viability detection in 3D culture systems and complements the limitations of two-dimensional plate-based methods in spheroids or organoids | |
Luminescent Cell Viability Assay Kit | BioReagent, for chemiluminescence | Suitable for luminescence-based cell viability analysis as a supplementary metabolic activity validation method beyond colorimetric assays |
Table 6. Supplementary validation products for cytotoxicity experiments
Catalog No. | Name | Grade and Purity | Suitable Research Use/Application |
CFDASE cell proliferation and tracing detection kit | — | Suitable for distinguishing “slowed cell proliferation” from “true increase in cytotoxicity,” thereby helping interpret the cause of decreased MTT/CCK-8 signals | |
EdU Cell Proliferation Detection Kit (6-FAM) | BioReagent, biological stain, for microscopy, suitable for fluorescence analysis | Suitable for supplementary analysis of proliferative capacity and for distinguishing proliferation inhibition from cytotoxic effects | |
EdU Cell Proliferation Detection Kit (AF488) | Bioactive, biological stain, for microscopy, suitable for fluorescence analysis | Suitable for fluorescence-based proliferation validation and as a supplementary proliferation indicator for cytotoxicity results | |
EdU Cell Proliferation Detection Kit (AF594) | BioReagent, biological stain, for microscopy, suitable for fluorescence analysis | Suitable for microscopy-based proliferation analysis and is more informative when interpreted together with viability/toxicity results | |
EdU Cell Proliferation Detection Kit (AF647) | BioReagent, biological stain, for microscopy, suitable for fluorescence analysis | Suitable for proliferation analysis in multicolor fluorescence systems and can serve as a supplementary indicator for high-content imaging | |
Aladdin ® 555 click it edu universal cell proliferation detection kit (orange red fluorescence) | — | Suitable for proliferation analysis in multicolor imaging conditions and improves interpretive depth when combined with toxicity assays | |
Annexin V- AF488/PI Apoptosis Detection Kit | Suitable for immunofluorescence (IF), BioReagent, biological stain, for microscopy, ready-to-use | Suitable for stratified analysis of apoptosis and cell death mode, providing supplementary interpretation of the source of cytotoxicity | |
Annexin V- AF647/PI Apoptosis Detection Kit | Suitable for immunofluorescence (IF), BioReagent, biological stain, for microscopy, ready-to-use | Suitable for apoptosis stratification in multicolor fluorescence systems and supplements mechanistic interpretation of toxicity | |
Annexin V-APC/PI Apoptosis Detection Kit | BioReagent, biological stain, for microscopy, suitable for immunofluorescence (IF) | Suitable for stratified analysis of apoptosis and necrosis and helps interpret the death mode associated with metabolic decline | |
Annexin V-FITC/PI Apoptosis Detection Kit | Suitable for immunofluorescence (IF), BioReagent, biological stain, for microscopy | Suitable for microscopy-based apoptosis stratification and provides more robust interpretation when combined with MTT/CCK-8 results | |
Hoechst 33258/PI Double Staining Kit | BioReagent, biological stain, for microscopy, ready-to-use | Suitable for nuclear morphology analysis and identification of PI-positive cells, supplementing morphologic information on cell death | |
Hoechst 33342/PI Apoptosis Detection Kit | BioReagent, biological stain, for microscopy, ready-to-use | Suitable for observing apoptotic and necrotic morphology and helps interpret the death type corresponding to plate-based colorimetric results | |
Colorimetric TUNEL Apoptosis Assay Kit | BioReagent, colorimetric method, for microscopy | Suitable for apoptosis validation at the level of DNA fragmentation and serves as supplementary evidence for late-stage toxic injury | |
Aladdin ® 488 TUNEL apoptosis Kit (green fluorescence) | — | Suitable for fluorescence-based DNA fragmentation detection and supplements mechanistic analysis of terminal toxic injury | |
Aladdin ® 555 TUNEL apoptosis Kit (orange red fluorescence) | — | Suitable for apoptosis validation in multicolor imaging and can strengthen interpretive depth when combined with viable-cell signals | |
Aladdin ® 594 TUNEL apoptosis Kit (red fluorescence) | — | Suitable for validation of late-stage DNA fragmentation after cell death and as a supplementary toxicity endpoint indicator | |
Aladdin ® 640 TUNEL apoptosis Kit (far red fluorescence) | — | Suitable for apoptosis analysis in the far-red channel and convenient for use in multicolor imaging systems | |
Cell Cycle and Apoptosis Analysis Kit | BioReagent, molecular biology grade | Suitable for distinguishing cell-cycle arrest from increased cell death and supplements interpretation of reduced viability signals | |
Cell Cycle and Apoptosis Analysis Kit | BioReagent, for microscopy, biological stain, suitable for immunofluorescence (IF), suitable for fluorescence analysis, for cell culture, ready-to-use, for DNA and RNA applications, sterile-filtered | Suitable for combined evaluation of cell cycle and apoptosis and can strengthen layered interpretation of cytotoxicity mechanisms | |
JC-1 | ≥95% | Suitable for detection of changes in mitochondrial membrane potential and supplements interpretation of whether MTT/CCK-8 decline is associated with mitochondrial injury | |
JC-10 | ≥95% | Suitable for supplementary mitochondrial function analysis and cytotoxicity mechanism validation | |
Mitochondrial Membrane Potential Assay Kit (Rhodamine 123) | BioReagent, for cell culture, sterile | Suitable for evaluation of mitochondrial functional status in cytotoxicity studies and supplements metabolic assay conclusions | |
Mitochondrial Membrane Potential Detection Kit (JC-1) | — | Suitable for validation of mitochondrial depolarization and toxicity mechanisms | |
Mitochondrial Membrane Potential Assay Kit (JC-10) | BioReagent | Suitable for mitochondrial membrane potential detection and as a supplementary indicator for metabolism-based toxicity analysis | |
Reactive Oxygen Species Assay Kit | — | Suitable for analysis of oxidative stress levels and supplements mechanistic interpretation of cytotoxicity induced by drugs, nanomaterials, and complex samples | |
Mitochondrial Reactive Oxygen Species (ROS) Production Rate Assay Kit (Fluorometric Method) | BioReagent | Suitable for analysis of mitochondrial oxidative stress and for evaluating whether metabolic decline is accompanied by mitochondrial injury |
8. Result evaluation and quality control
8.1 Key control points in experimental design
(1) Seeding density
If cell density is too high, metabolic assay signals may saturate too early. If density is too low, statistical stability is reduced.
(2) Time-point design
Different methods respond differently to early-stage and late-stage injury, so time-point design should match the research objective.
(3) Blank and background controls
Cell-free blank wells, sample background wells, and medium background wells are essential settings in experiments involving complex samples.
8.2 Common pitfalls in data interpretation
(1) Directly equating absorbance with cell number
This ignores the fact that these methods read out cell functional status rather than absolute cell counts.
(2) Directly equating a single-method result with death rate
This extrapolation is usually too strong, especially for the Neutral Red assay and CCK-8 assay.
(3) Ignoring chemical interference from the sample itself
Many abnormal toxicity results arise first from methodological issues rather than true biologic effects of the sample.
8.3 More robust ways of expressing results
(1) Neutral Red assay
More appropriately described as relative Neutral Red uptake capacity or relative lysosomal functional signal.
(2) MTT/CCK-8 assays
More appropriately described as relative metabolic activity or relative dehydrogenase activity signal.
(3) Integrated conclusions
A clear toxicity conclusion should be based on cross-validation from methods with different principles, rather than relying on a single method alone.
The differences among the Neutral Red assay, the MTT assay, and the CCK-8 assay fundamentally reflect differences in detection dimension. The Neutral Red assay is suitable for supplementary evaluation of organelle function, the MTT assay is suitable for traditional endpoint metabolic analysis, and the CCK-8 assay is suitable for high-throughput and multi-time-point detection. In studies requiring robust conclusions, method selection should be organized into a layered detection strategy based on the research objective, sample properties, and interference risk.